Cargando…
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning these changes...
Autores principales: | Carraway, Hetty E., Malkaram, Sridhar A., Cen, Yana, Shatnawi, Aymen, Fan, Jun, Ali, Hamdy E. A., Abd Elmageed, Zakaria Y., Buttolph, Thomm, Denvir, James, Primerano, Donald A., Fandy, Tamer E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316973/ https://www.ncbi.nlm.nih.gov/pubmed/32587297 http://dx.doi.org/10.1038/s41598-020-67170-8 |
Ejemplares similares
-
Author Correction: Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
por: Carraway, Hetty E., et al.
Publicado: (2020) -
Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents
por: Malkaram, Sridhar A, et al.
Publicado: (2022) -
Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells
por: Sawesi, Suhila, et al.
Publicado: (2022) -
Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017) -
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents
por: Gallimore, Fallon, et al.
Publicado: (2023)